| Trial | Generation of allocation sequence | Allocation concealment | Blinding | Inclusion of all randomized participants |
| Bock 1990 | Unclear | Unclear | Single | Adequate |
| Eder 2003i | Unclear | Unclear | Double | Adequate |
| Eder 2003ii | Unclear | Unclear | Double | Adequate |
| Ehrlich 2003 | Adequate | Unclear | Double (first 2 doses) and open (for dose 3) | Adequate |
| Girgsdies 1996 | Unclear | Unclear | Double | Adequate |
| Harabacz 1992 | Unclear | Unclear | Double | Adequate |
| Immuno 1996 | Adequate | Adequate | Double | Adequate |
| Loew‐Baselli 2006 | Unclear | Unclear | Single (participants) | Adequate |
| Pavlova 1999 | Unclear | Unclear | Not mentioned | Inadequate for efficacy adequate for safety |
| Schoendorf 2007 | Unclear | Unclear | Open | Adequate |
| Schöndorf 2007 | Unclear | Unclear | Open | Inadequate for efficacy and unclear for safety |